Studies have found that jumonji domain containing 3 (JMJD3) may serve as an important epigenetic therapeutic target and/or prognostic predictor in GC, and that inhibiting JMJD3 might offer an effective therapeutic strategy for this cancer (175). This evidence concerns the gene KDM6B and cancer.